A5058826300- Autoimmune Neurological Disorders and Treatments
- Peripheral Neuropathies and Disorders
- Genetics and Neurodevelopmental Disorders
- Infectious Encephalopathies and Encephalitis
- Neurological and metabolic disorders
- Cellular transport and secretion
- RNA regulation and disease
- Cancer Immunotherapy and Biomarkers
- Health, Medicine and Society
- Healthcare Systems and Practices
- Peripheral Nerve Disorders
- Cytomegalovirus and herpesvirus research
- Cervical and Thoracic Myelopathy
- Brain Metastases and Treatment
- Spine and Intervertebral Disc Pathology
- Protein Tyrosine Phosphatases
- Parkinson's Disease Mechanisms and Treatments
- interferon and immune responses
- Historical and Scientific Studies
- Pharmacological Effects and Toxicity Studies
- Epilepsy research and treatment
Inserm
2017-2024
Université Claude Bernard Lyon 1
2017-2024
Centre National de la Recherche Scientifique
2017-2024
Centre Hospitalier Universitaire de Clermont-Ferrand
2014-2024
Hospices Civils de Lyon
2018-2023
Stanford University
2023
Neuro-Dol
2023
Centre Hospitalier Gabriel-Martin
2020
Service de la Santé Publique
2020
Université Clermont Auvergne
2017
<h3>Background and Objectives</h3> To report the clinical, biological, imaging features clinical course of a French cohort patients with glial fibrillary acidic protein (GFAP) autoantibodies. <h3>Methods</h3> We retrospectively included all who tested positive for GFAP antibodies in CSF by immunohistochemistry confirmed cell-based assay using cells expressing human GFAPα since 2017 from 2 referral centers. <h3>Results</h3> identified 46 antibodies. Median age at onset was 43 years, 65% were...
To describe the spectrum and outcome of central nervous system complications associated with immune checkpoint inhibitors (CNS-ICI).Patients CNS-ICI were identified their characteristics compared ICI-related peripheral neuropathy (PN-ICI).We 19 patients CNS-ICI. The receiving nivolumab (n=8), pembrolizumab (n=6), a combination ipilimumab-nivolumab (n=3), ipilimumab-durvalumab (n=1), or atezolizumab (n=1). Underlying malignancies included non-small-cell lung cancer melanoma other less common...
<h3>Objective:</h3> To report 10 patients with limbic encephalitis (LE) and adenylate kinase 5 autoantibodies (AK5-Abs). <h3>Methods:</h3> We conducted a retrospective study in cohort of 50 LE uncharacterized identified specific target using immunohistochemistry, Western blotting, immunoprecipitation, mass spectrometry, cell-based assay. <h3>Results:</h3> AK5 (a known autoantigen LE) was as the antibodies CSFs sera (median age 64 years; range 57–80), which characterized by subacute...
Relapses occur in 15%-25% of patients with leucine-rich glioma-inactivated 1 antibody (LGI1-Ab) autoimmune encephalitis and may cause additional disability. In this study, we clinically characterized the relapses identified factors predicting their occurrence.
Autoimmune encephalitis (AE) with antibodies against LGI1 and IgLON5 are clinically distinctive but share some particularities such as a strong association specific human leukocyte antigen (HLA) class II alleles. We describe patient double positivity for antibodies. In addition, we conducted immunodepletion the patient's serum HLA typing investigated presence of in cohort 23 anti-LGI1 patients carrying predisposing anti-IgLON5 encephalitis. A 70-year-old woman history lymphoepithelial...
Abstract Background Glial fibrillary acidic protein (GFAP) is expressed by astrocytes in the central nervous system (CNS), but also immature and regenerative Schwann cells peripheral (PNS). GFAP antibodies (GFAP-Abs) cerebrospinal fluid (CSF) have been mainly described patients with meningoencephalomyelitis. We aimed to study PNS symptoms CSF GFAP-Abs. Methods retrospectively included all tested positive for GFAP-Abs immunohistochemistry confirmed cell-based assay expressing human GFAPα...
Objective: The main purpose of this study was to assess the clinical feasibility diffusion tensor imaging (DTI) for diagnosis chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Background: Additionnal criteria such as plexus MRI is rarely used explore CIDP, mainly due lack accessibility and absence consensual protocol exploration plexuses nerve roots. Design/Methods: Between March 2013 December 2015, we prospectively enrolled 15 patients with definite CIDP according EFNS 2010...